DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,893,083 B2 Mandrea (45) Date of Patent: Feb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,893,083 B2 Mandrea (45) Date of Patent: Feb US007893O83B2 (12) United States Patent (10) Patent No.: US 7,893,083 B2 Mandrea (45) Date of Patent: Feb. 22, 2011 (54) METHOD OF TREATING GENITAL HERPES 6,491,940 B1 12/2002 Levin ......................... 424/434 6,569.435 B1 5/2003 Punnonen et al. (76) Inventor: Euges Madrillege Dr., 6,576,757 B1 6/2003 Punnonen et al. alos Heights, IL (US) 6,890,904 B1 5/2005 Wallner et al. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b)(b) bybV 96 days.ayS (Continued) (22) Filed: May 1, 2008 Arrese, Jorge E., et al., “Dermal Dendritic Cells in Anogenital Warty O O Lesions Unresponsive to an Immune-Response Modifier.” 2001, pp. (65) Prior Publication Data 131-134, Journal of Cutaneous Pathology, vol. 28. US 2008/O269274 A1 Oct. 30, 2008 (Continued) Related U.S. Application Data Primary Examiner San-ming Hui (63) Continuation-in-part of application No. 1 1/318,659, Assistant Examiner Kathrien Cruz filed on Dec. 21, 2005, now abandoned, which is a (74) Attorney, Agent, or Firm—James P. Muraff; Neal, continuation-in-part of application No. 1 1/109,553, Gerber & Eisenberg LLP filed on Apr. 19, 2005, now abandoned, which is a continuation-in-part of application No. 10/751,371, (57) ABSTRACT filed on Jan. 5, 2004, now abandoned. (60) Rinal application No. 60/438,431, filed on Jan. The present invention is directed to a method of increasing the s time period between outbreaks of genital herpes comprising (51) Int. Cl. providing an imidazoquinolinamine formulation, disposing AOIN 43/42 (2006.01) an amount of the imidazoquinolinamine formulation into a A6 IK 39/00 (2006.01) first nare of an individual infected with Herpes Simplex Virus A6 IK 39/245 (2006.01) type 2, covering at least a portion of the internal Surface of the (52) U.S. Cl 514/293: 424/229.1: 424/231.1 individual’s first nare with a portion of the amount of the (58) Field O f Classification search • us 514293 imidazoquinolinamine in the nare, massaging the portion of See application file for com lete search histo the amount of the imidazoquinolinamine into the internal pp p ry. Surface of the first nare, disposing the amount of the imida (56) References Cited Zoquinolinamine formulation into a second nare of the indi vidual, covering at least a portion of the internal Surface of the U.S. PATENT DOCUMENTS second nare with a portion of the amount of the imidazo 3,608,065. A * 9, 1971 Lover et al. ................... 424/45 quinolinamine in said nare and- 0 massaging the portion of the 6,039,969 A * 3, 2000 Tomai et al. ................ 424/434 amount of the imidazoquinolinamine into the internal Surface 6,147,086 A 1 1/2000 Brenman of said nare. 6,245,776 B1 6/2001 Skwierczynski et al. 6,361,769 B1 3/2002 Tovey 13 Claims, 6 Drawing Sheets US 7,893,083 B2 Page 2 U.S. PATENT DOCUMENTS E. Stockfleth et al., “Successful Treatment of Actinic Keratosis with Imiquimod Cream 5%: a Report of Six Cases.” British Journal of 2003/O139364 A1* 7/2003 Krieg et al. ................... 514,44 Dermatology 2001: 144: pp. 1050-1053. 2004, OO67953 A1 4/2004 Stein et al. Alicia R. Barba, "An OpenLabel Safety Study of Topical Imiquimod 2004/O136917 A1 7/2004 Mandrea 5% Cream in the Treatment of Molluscum Contagiosum in Chil dren.” Dermatology Online Journal, Jun. 25, 2006, vol. 7, No. 1, pp. OTHER PUBLICATIONS 1-6. Bishop, Gail A., “The Immune Response Modifier Resiguimod Mim Theresa L. Schroeder, "Squamous Cell Carcinoma in Situ of the ics CD40-Induced B Cell Activation.” Mar. 8, 2001, pp. 9-17. Cellu Penis Successfully Treated with Imiquimod 5% Cream.” JAm Acad lar Immunology, vol. 208, Academic Press. Dermatol, Apr. 2002, vol. 46, No. 4, pp. 545-548. Dahl, Mark V. “Imiquimod: A Cytokine Inducer.” Oct. 2002, pp. Robin Marks, "Imiquimod 5% Cream in the Treatment of Superficial S205-S208, J. Am. Acad. Dermatol., vol. 47, No. 4, American Acad Basal Cell Carcinoma: Results of a Multicenter 6-Week Dose-Re emy of Dermatology, Inc. sponse Trial.” J Am Acad Dermatol, May 2001, vol. 44, No. 5, pp. Dockrell, D. H., Imiquimod and Resiguimod as Novel 807-813. immunomodulators, 2001, pp. 751-755, Journal of Antimicrobial Claus Oster-Schmidt, “Imiquimod: A New Possibility for Treatment Chemotherapy, vol. 48, The British Society for Antimicrobial Che Resistant Verrucae Planae.” Arch Dermatol, vol. 137, May 2001, pp. motherapy. 666-667. Gibson. Sheila J., et al., “Plasmacytoid Dendritic Cells Produce Abstracts, The Journal of Investigative Dermatology, p. 584, Oct. Cytokines and Mature in Response to the TLR7 Agonists, Imiquimod 1989. and Resiguimod.” 2002, pp. 74-86, Cellular Immunology, vol. 218, SJ Gibson et al., “Oral R-837 Induces a Interferon in Cynomologus Elsevier Science, USA. Mon.” Journal of Interferon Research, vol. 10, issue Suppl. 1, 1990, Hemmi, Hiroaki, et al., “Small Anti-Viral Compounds Activate p. S124. Immune Cells Via the TLR7MyD88-Dependent Signaling Pathway.” Michael J. Reiter, et al., “Cytokine Induction in Mice by the Jan. 22, 2002, pp. 196-200, Nature Immunology, vol. 3, No. 2, Nature Immunomodulator Imiquimod.” Journal of Leukocyte Biology, vol. Publishing Group. 55, Feb. 1994, pp. 234-240. O'Mahony, C., et al., “New Patient-Applied Therapy for Anogenital Mark Marsh et al., “Endocytosis in Viral Replication.” Traffic 2000 1: Warts is Rate Favourably by Patients.” Sep. 2001, pp. 565-570, Inter pp. 525-532. national Journal of STD & AIDS, vol. 12. Bart L. Haagmans et al., “Pegylated Interferon-a. Protects Type 1 Stanley, M.A., “Imiquimod and the Imidazoquinolones: Mechanism Pneumocytes Against SARS Coronavirus Infection in Macaques.” of Action and Therapeutic Potential.” 2002, pp. 571-577. Clinical and Nature Medicine, vol. 10, No. 3, Mar. 2004 pp. 290-293. Experimental Dermatology, vol. 27. Blackwell Science Ltd. Sabine Mihm et al., “Interferon Type I Gene Expression in Chronic Clean, Sanda, et al., “Immune Responses Induced by Intranasal Hepatitis C.” Laboratory Investigation (2004) 84, pp. 1148-1159. Imiquimod and Implications for Therapeutics in Rhinovirus Infec Ron A.M. Fouchier et al., “Detection of Influenza A Viruses from tions.” 2005, pp. 457-461, J. Cell, Mol. Med., vol. 9, No. 2. Different Species by PCR. Amplification of Conserved Sequences in Gaspari, Anthony A., et al., “Immunotherapy of Basal Cell Carci the Matrix Gene.” Journal of Clinical Microbiology, vol. 38, No. 11, noma: Evolving Approaches.” Oct. 2003, pp. 1027-1034, American Nov. 2000, pp. 4096-4101. Society for Dermatologic Surgery, Inc., vol. 29, No. 10, Blackwell Louis DeTulleo et al., “The Clathrin Endocytic Pathway in Viral Publishing, Inc. Infection.” The EMBOJournal, vol. 17, No. 16, 1998, pp. 4585-4593. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Sara Cherry et al., “Entry is a Rate-Limiting Step for Viral Infection 7th Edition, pp. 170-171, 2007. in a Drosophila melanogaster Model of Pathogenesis.” Nature Hendeles (Abstract, Selecting a Decongestant, Pharmacotherapy, Immunology, vol. 5, No. 1, Jan. 2004, pp. 81-87. Nov./Dec. 1993, 13, pp. 129S-134S). Timothy W. Schacker et al., “Imiquimod 5% Cream Does Not Alter C.J. Harrison et al., “Modification of Immunological Responses and the Natural History of Recurrent Herepes Genitalis: a Phase II, Ran Clinical Disease During Topical R-837 Treatment of Genital HSV-2 domized, Double-Blind, Placebo-Controlled Study”. Antimicrobial Infection.” Antiviral Research, 10 (1988), pp. 209-223. Agents and Chemotherapy, vol. 46, No. 10, Oct. 2002, pp. 3243 Kathleen J. Smith et al., “Squamous Cell Carcinomain Situ (Bowen's 3248. Disease) in Renal Transplant Patients Treated with 5% Imiquimod David I. Bernstein et al., “Evaluation of Imiquimod 5% Cream to and 5% 5-Fluorouracil Therapy,”, Dermatol Surg 2001; 27: pp. 561 Modify the Natural History of Herpes Labialis: A Pilot Study.” Clini 564. cal Infectious Diseases, 2005:41, pp. 808-814. Nuria Verdaguer et al., "X-ray Structure of a Minor Group Human PCT International Search Report and Written Opinion dated May 21, Rhinovirus Bound to a Fragment of its Cellular Receptor Protein.” 2008 for PCT/USO6.14803. Nature Structural & Molecular Biology, vol. 11, No. 5, May 2004, pp. Office Action dated Jun. 20, 2007 for U.S. Appl. No. 10/751,371. 429-434. Office Action dated Aug. 19, 2008 for U.S. Appl. No. 1 1/318,659. “Correspondence.” British Journal ofIDermatology 2002: 146: pp. Office Action dated Sep. 16, 2008 for U.S. Appl. No. 1 1/109.553. 331-344. * cited by examiner U.S. Patent Feb. 22, 2011 Sheet 1 of 6 US 7,893,083 B2 F.G. 1 U.S. Patent Feb. 22, 2011 Sheet 2 of 6 US 7,893,083 B2 21 U.S. Patent Feb. 22, 2011 Sheet 3 of 6 US 7,893,083 B2 U.S. Patent Feb. 22, 2011 Sheet 4 of 6 US 7,893,083 B2 Imiquimod Myd88 Signaling Ya Cascade lmmature Antigen- IFN-o, IL-12, L-18 Presenting Cells Antigen N Presentation s A. CytokinesEffector Š SS IL-4 & Costimulatory (2S Mature Antigen- Molecules N IL-4, L-5 Presenting Cells V it. 3. FIG. 4 NH2 NH2 N1 N-N N1 n-N o-/ 2NNy 2NN X-1 Imiquimod (R-837) Resiguimod (R-848) F.G. 5 Time (hours) F.G. 6B U.S. Patent Feb. 22, 2011 Sheet 6 of 6 US 7,893,083 B2 Time (hours) F.G. 7 - 10.00 a1 E 1.00 E E 2 S. o. 10 t 9 0.01 Treated Untreated F.G. 8 US 7,893,083 B2 1.
Load more

Recommended publications
  • Efficacy and Safety of Imiquimod for Verruca Planae: a Systematic Review
    Global Dermatology Research Article ISSN: 2056-7863 Efficacy and safety of imiquimod for verruca planae: A systematic review Xin-rui Zhang#, Bi-huan Xiao#, Rui-qun Qi*, and Xing-hua Gao* Department of Dermatology, No 1 Hospital of China Medical University, Shenyang 110001, PR China #These authors contributed equally to this work Abstract Objective: To assess the efficacy and safety of imiquimod for treating verruca planae. Methods: We searched the Pubmed, Cochrane Register of Controlled Trials, EMbase, CBM, CNKI and Wanfang databases (Chinese) to collect randomized controlled trials (RCTs). We screened the retrieved studies according to the predefined inclusion and exclusion criteria, evaluated the quality of include studies, and performed meta-analyses using the Cochrane Collaboration’s RevMan 5.1. Software. Results: Twenty-six RCTs involving 2169 patients with verruca planae were included and assessed. At the end of the 6th and ≥8th week, the effective rate of topical imiquimod was obviously higher than that of control [ RR=1.42, 95%CI (1.27, 1.60), P <0.00001; RR=1.43, 95%CI (1.22,1.67), P<0.00001]. The effective rate of imiquimod cream was higher than tretinoin cream, tazarotene gel and other antiviral drugs. [RR=1.41, 95%CI (1.25, 1.59), P <0.00001; RR=1.76, 95%CI (1.48, 2.10), P<0.00001; RR=1.71, 95%CI (1.29, 2.26), P =0.0002]. However, the effectiverate of imiquimod cream was lower than 5-ALA-PDT (RR=0.6, 95%CI (0.5, 0.71), P<0.00001). Conclusions: The limited evidence demonstrates that topical imiquimod is safe and efficient.
    [Show full text]
  • Treating the Oral Creeper: Herpes
    ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.08.001639 Karthik D Yadav. Biomed J Sci & Tech Res Short Communication Open Access Treating the Oral Creeper: Herpes Yadav Karthik D1*, Pai Anuradha2, R Shesha Prasad3, Yaji Anisha4 1M.D.S - Master of Dental surgery, Department of oral medicine and radiology, Bangalore 2HOD & Professor, Department of oral medicine and radiology, The oxford dental college and research center, Bangalore 3M.D.S - Master of Dental surgery, Department of oral medicine and radiology, Senior lecturer, The oxford dental college and research center, Bangalore 4M.D.S – Master of Dental surgery, Department of oral medicine and radiology, Bangalore Received: August 19, 2018; Published: August 24, 2018 *Corresponding author: Karthik D Yadav, 10th Milestone, Bommanahalli, Hosur Road, Bangalore-560 102, India Short Communication combination of all these drugs is more effective in treating HSV The term “herpes” creates panic among the general population. infections than the anesthetic preparations alone. They are also Oral herpes simplex virus is most commonly seen affecting the oral soft tissue region the perioral area [1,2]. They have been categorized treating HSV. Further, ice can be used and lip materials containing into HSV -1 and HSV -2, wherein HSV-1 affects the orofacial region, used with systemic antiviral agents for increased efficacy while cocoa, lanolin and petroleum products have been recommended to most commonly above the waist region and HSV-2 affects the treat recurrent herpes [6]. genital region below the waist. However, change in sexual practices have been the basis for the variations of the virus, affecting the While the use of topical drugs has few adverse effects and are non-conventional regions of the body [3,4].
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • Breast Cancer Treatment with Imiquimod: Applying an Old Lotion to a New Disease
    Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Breast cancer treatment with imiquimod: Applying an old lotion to a new disease Holbrook Kohrt, MD PhD Stanford University Cancer Institute Department of Medicine, Division of Oncology Stanford, CA 94305 Title: 79 characters Abstract: 49 words Text: 1200 words References: 12 references The author has no conflicts of interest. Running Title: Applying an old lotion to a new disease Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-3138 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Over the prior two decades, imiquimod, a toll-like receptor 7 agonist, has been applied to nearly fifty clinical settings. Due to its immunomodulatory role, the topical cream today for the first time, is being applied to cutaneous breast cancer in pre-clinical models and in a Phase 2 clinical trial. Manuscript In this issue of Clinical Cancer Research, two sets of authors from Demaria’s group, Dewan et al. (1) and Adams et al. (2) detail in companion papers the anti-tumor efficacy of imiquimod in first, a preclinical breast cancer model in combination with radiation (1), and second, a Phase 2, breast cancer clinical trial assessing safety and immunologic activity (2). Fifteen years after first approval by the Food and Drug Administration (FDA), imiquimod remains the only approved, active toll-like receptor (TLR) agonist (3).
    [Show full text]
  • Imiquimod Enhances IFN-Γ Production and Effector Function of T Cells
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE Imiquimod Enhances IFN-c Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin Susan J. Huang1, Dirkjan Hijnen2, George F. Murphy3, Thomas S. Kupper1, Adam W. Calarese1, Ilse G. Mollet4, Carl F. Schanbacher1, Danielle M. Miller1, Chrysalyne D. Schmults1 and Rachael A. Clark1 Squamous cell carcinomas (SCCs) are sun-induced skin cancers that are particularly numerous and aggressive in patients taking T-cell immunosuppressant medications. Imiquimod is a topical immune response modifier and Toll-like receptor 7 (TLR7) agonist that induces the immunological destruction of SCC and other skin cancers. TLR7 activation by imiquimod has pleiotropic effects on innate immune cells, but its effects on T cells remain largely uncharacterized. Because tumor destruction and formation of immunological memory are ultimately T-cell-mediated effects, we studied the effects of imiquimod therapy on effector T cells infiltrating human SCC. SCC treated with imiquimod before excision contained dense T-cell infiltrates associated with tumor cell apoptosis and histological evidence of tumor regression. Effector T cells from treated SCC produced more IFN-g, granzyme, and perforin and less IL-10 and transforming growth factor-b (TGF-b) than T cells from untreated tumors. Treatment of normal human skin with imiquimod induced activation of resident T cells and reduced IL-10 production but had no effect on IFN-g, perforin, or granzyme, suggesting that these latter effects arise from the recruitment of distinct populations of T cells into tumors.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Treatment of Viral Infections Including COVID-19
    Treatment of Viral Infections including COVID-19 Dr. Sujith J Chandy MBBS., MD., PhD., FRCP(Edin) Director, ReAct Asia Pacific Professor, Clinical Pharmacology Christian Medical College, Vellore, India 1 What is a Virus? An infective agent (intracellular parasite) …… ….. consists of a nucleic acid molecule in a protein coat / capsid …..able to multiply only within the living cells of a host 2 Types of Virus DNA VIRUS RNA VIRUS Rhabdo virus Pox virus Rubella virus Herpes virus Picorna virus Adeno virus Orthomyxo virus Hepadna virus Paramyxo virus Papilloma virus Retro virus Corona virus Most DNA viruses assemble in the nucleus; most RNA viruses in cytoplasm 3 The more ‘in’famous viruses in the last decade 4 Stages of viral replication & Targets for treatment Cell Entry Uncoating Translation of viral proteins Posttranslational modification Release 5 Mechanisms of anti-viral action • Inhibition of viral enzymes -viral DNA and RNA polymerase • Viral protein glycosylation, virus assembly, new virus particle transport, and virus release. • Other mechanisms -inhibition of ACE2 cellular receptor. • Acidification at the surface of the cell membrane inhibiting fusion of the virus, and immunomodulation of cytokine release 6 Problems with antiviral therapy • Drugs interfere with host cell metabolism: – this can lead to adverse effects • Adequate concentrations of drug need to be accumulated inside cell: - for good effect • Peak viral replication associated with symptoms: – therapy must be started earlier to be effective 8 Acyclovir • Guanosine derivative • Mechanism: 1. Inhibits herpes virus DNA polymerase 2. Incorporated into viral DNA – stops DNA strand elongation • PK – widely distributed, enters CSF & cornea • Preparations – tablet, vial, cream, eye ointment • ADR – burning sensation (topical), rashes (IV) Acyclovir - Uses • Genital Herpes Simplex • Mucocutaneous HSV • HSV encephalitis – IV therapy • HSV keratitis – eye ointment • Herpes Zoster – IV or oral.
    [Show full text]
  • Immunosuppressant Ingredients, Immunostimulant Ingredients
    Immunosuppressant Ingredients, Immunostimulant Ingredients Immunosuppressant Ingredients Immunosuppressant ingredients are chemical and medicinal agents used for the suppression and regulation of immune responses. Pharmacologically speaking, these agents have varied mecha- nisms of action, such as regulation of inflammatory gene expression, suppression of lymphocyte signal transduction, neutralization of cytokine activity, and inhibition lymphocyte proliferation by agent-induced cytotoxicity. Common agents include glucocorticoids, alkylating agents, metabolic antagonists, calcineurin inhibitors, T-cell suppressive agents, and cytokine inhibitors. 5-Aminosalicylic Acid 25g / 500g [A0317] 5-Aminosalicylic acid (5-ASA) is commonly used as a gastrointestinal anti-inflammatory agent. It has in vitro and in vivo pharmacologic effects that decrease leukotriene production, scavenge for free radicals, and inhibits leukocyte chemotaxis et al. Azathioprine 5g / 25g [A2069] Azathioprine is a prodrug of 6-mercaptopurine (6-MP), which inhibits the synthesis of purine ribonucleotides and DNA/RNA. Cyclophosphamide Monohydrate 5g / 25g [C2236] Cyclophosphamide is an antitumor alkylating reagent involved in the cross-linking of tumor cell DNA. Cyclosporin A 100mg / 1g [C2408] Cyclosporin A is a cyclic polypeptide immunosuppressant. It inhibits the activity of T-lymphocytes, and the phosphatase activity of calcineurin. Dimethyl Fumarate 25g / 500g [F0069] Dimethyl fumarate has neuroprotective and immunomodulating effects. Fingolimod Hydrochloride 200mg / 1g [F1018] Fingolimod (FTY720) is an immunomodulatory agent. It is an agonist at sphingosine 1-phosphate (S1P) receptors, and inhibits lymphocyte emigra- tion from lymphoid organs. Iguratimod 25mg / 250mg [I0945] Iguratimod (T-614) is an agent with anti-inflammatory and immunomodulatory activities. Its activity functions by the inhibiting production of immune globulin and inflammatory cytokines such as TNF-α, IL-1β and IL-6, and used as a disease modifying anti-rheumatic drug (DMARD).
    [Show full text]
  • The Management of Diycult Anogenital Warts
    192 Sex Transm Inf 1999;75:192–194 The management of diYcult anogenital warts Clinical Sex Transm Infect: first published as 10.1136/sti.75.3.192 on 1 June 1999. Downloaded from A McMillan knots Patients with anogenital warts present the extensive and persistent. As regression often healthcare professional with two major occurs within several weeks of delivery, treat- problems—recurrence and persistence. These ment is usually unnecessary. Occasionally, problems occur because of persistence of however, the warts cause discomfort, and these human papillomavirus in keratinocytes, defec- may be treated with cryotherapy or trichloro- tive immune responses in individuals with per- ethanoic acid (TCA). Conventional therapy is sistence and recurrence of warts, and the lack not uniformly successful in the treatment of of specific antiviral therapy. warts in the immunocompromised patient, In this article, the discussion will be confined including HIV infected individuals, and immu- to the management of lesions visible to the notherapy is generally unsatisfactory; it is not, naked eye and a scheme of management that I however, the purpose of this article to discuss have found useful is shown in figure 1. this issue further. The hyperplastic condylomata acuminata In deciding on treatment of persistent that have been present for less than 3 months, lesions, it is worth considering the following: often clear quickly after treatment with podo- Size and number of the lesions—Many indi- phyllin, podophyllotoxin, or cryotherapy. Podo- viduals have a few warts that are less than 1 mm phyllotoxin appears to be more eVective than in diameter and reassurance that spontaneous podophyllin in clearing warts and it has the regression will eventually occur, together with added advantage that the patient can apply it.
    [Show full text]
  • Local Therapy with Imiquimod As a Possible Medical Treatment of Vulvar Intraepithelial Neoplasms
    Original article UDC: 618.16:615.2:616-085 doi:10.5633/amm.2019.0101 LOCAL THERAPY WITH IMIQUIMOD AS A POSSIBLE MEDICAL TREATMENT OF VULVAR INTRAEPITHELIAL NEOPLASMS Dane Krtinić1,2, Radomir Živadinović3,4, Biljana Živadinović5,6, Zorica Jović1, Srdjan Pešić1, Voja Pavlović7, Svetlana Pavlović8,9, Milena Trandafilović10, Dragana Stokanović1, Gorana Nedin-Ranković1, Ana Cvetanović2,11, Ilinka Todorovska2, Nikola Živković12,13, Maša Golubović14,15 Imiquimod is a local immunomodulator with antiviral effects. Vulvar intraepithelial neoplasia is a chronic precancerous condition of the skin of the vulva, with different malignant potential and clinical course. The aim of the paper was to determine therapeutic effects of Imiquimod in treating different types and grades of vulvar intraepithelial neoplasms. The study enrolled 17 patients with vulvar pre-cancerous conditions of different grade and histological type. The patients were treated with combined medical therapy oral systemic immunomo- dulatory and antiviral drug - inosine acedoben dimepranol and 5% Imiquimod cream locally applied to the lesion area using cotton swabs. Complete remision (CR) had 41.18% of patients, partial remission (PR) was seen in 47.06%, and 11.76% of patients had no response (NR). Out of these patients, response distribution for usual type was: CR 80%, 20% NR, and for diffe- rentiated type the response distribution was: 8.3% NR, 66.67% PR, while 25% of patients had CR. The use of imiquimod for conservative treatment of vulvar intraepithelial neoplasia is a beneficial alternative to surgical treatment. The best results of imiquimod treatment are achiev- ed in younger patients with usual type of vulvar neoplasia, while the treatment effects are limited to partial response in older patients with differentiated VIN.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Revista6vol86v6 ING Layout 1
    1185 CASE REPORT ▲ Hypertrophic perianal herpes successfully treated with imiquimod * Herpes hipertrófico perianal tratado eficazmente com imiquimod Sara Isabel Alcântara Lestre1 Alexandre João2 Célia Carvalho3 Vasco Vieira Serrão2 Abstract: Herpes simplex virus type 2 (HSV-2) infections are frequent in HIV (human immunodeficiency virus) infected patients. In those cases, genital herpes may have an atypical clinical presentation. Hypertrophic and vegetating variants are unusual. The authors describe a case of hypertrophic perianal herpes in an HIV patient with unsatisfactory response to acyclovir and valacyclovir, successfully treated with imiquimod. Hypertrophic genital herpes cases are frequently refractory to antiviral treatments. In our experience, imiquimod is an efficient, safe and well tolerated treatment that should be considered in therapeutic approach of these patients. Keywords: Antiviral agents; Combined modality therapy; Efficacy; Herpes genitalis; Herpesvirus 2, human Resumo: A infecção pelo vírus herpes simples tipo 2 (HSV-2) é frequente em pacientes infetados pelo vírus de imunodeficiência adquirida (VIH). Nestes casos, o herpes genital pode ter uma apresentação clínica atí- pica. As variantes hipertróficas e vegetantes são pouco habituais. Os autores relatam um caso de herpes hipertrófico perianal em paciente infetada pelo VIH, com resposta insatisfatória ao aciclovir e valaciclovir, tratado eficazmente com imiquimod tópico. O herpes genital hipertrófico é, frequentemente, refratário aos tratamentos antivirais. Na nossa
    [Show full text]